Show simple item record

dc.contributor.authorZaman, Mehfuz
dc.contributor.authorChandrudu, Saranya
dc.contributor.authorGiddam, Ashwini K
dc.contributor.authorReiman, Jennifer
dc.contributor.authorSkwarczynski, Mariusz
dc.contributor.authorMcPhun, Virginia
dc.contributor.authorMoyle, Peter M
dc.contributor.authorBatzloff, Michael R
dc.contributor.authorGood, Michael F
dc.contributor.authorToth, Istvan
dc.date.accessioned2017-05-03T12:53:54Z
dc.date.available2017-05-03T12:53:54Z
dc.date.issued2014
dc.identifier.issn1743-5889
dc.identifier.doi10.2217/nnm.14.190
dc.identifier.urihttp://hdl.handle.net/10072/67262
dc.description.abstractAim: Utilize lipopeptide vaccine delivery system to develop a vaccine candidate against Group A Streptococcus. Materials & methods: Lipopeptides synthesized by solid-phase peptide synthesis-bearing carboxyl (C)-terminal and amino (N)-terminal Group A Streptococcus peptide epitopes. Nanoparticles formed were evaluated in vivo. Results: Immune responses were induced in mice without additional adjuvant. We demonstrated for the first time that incorporation of the C-terminal epitope significantly enhanced the N-terminal epitope-specific antibody response and correlated with forming smaller nanoparticles. Antigen-presenting cells had increased uptake and maturation by smaller, more immunogenic nanoparticles. Antibodies raised by vaccination recognized isolates. Conclusion: Demonstrated the lipopeptidic nanoparticles to induce an immune response which can be influenced by the combined effect of epitope choice and size.
dc.description.peerreviewedYes
dc.description.publicationstatusYes
dc.languageEnglish
dc.language.isoeng
dc.publisherFuture Medicine
dc.publisher.placeUnited Kingdom
dc.relation.ispartofstudentpublicationN
dc.relation.ispartofpagefrom2613
dc.relation.ispartofpageto2624
dc.relation.ispartofissue17
dc.relation.ispartofjournalNanomedicine
dc.relation.ispartofvolume9
dc.rights.retentionY
dc.subject.fieldofresearchProteins and peptides
dc.subject.fieldofresearchPhysical chemistry
dc.subject.fieldofresearchBacteriology
dc.subject.fieldofresearchMedical biotechnology
dc.subject.fieldofresearchNanotechnology
dc.subject.fieldofresearchApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)
dc.subject.fieldofresearchBiomedical engineering
dc.subject.fieldofresearchcode340407
dc.subject.fieldofresearchcode3406
dc.subject.fieldofresearchcode310701
dc.subject.fieldofresearchcode3206
dc.subject.fieldofresearchcode4018
dc.subject.fieldofresearchcode320402
dc.subject.fieldofresearchcode4003
dc.titleGroup A Streptococcal vaccine candidate: contribution of epitope to size, antigen presenting cell interaction and immunogenicity
dc.typeJournal article
dc.type.descriptionC1 - Articles
dc.type.codeC - Journal Articles
gro.facultyOffice of the Snr Dep Vice Chancellor, Institute for Glycomics
gro.hasfulltextNo Full Text
gro.griffith.authorGood, Michael F.
gro.griffith.authorZaman, Mehfuz


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

  • Journal articles
    Contains articles published by Griffith authors in scholarly journals.

Show simple item record